Psychiatry Education Forum

Gratitude Post: Celebrating 13 Years of Psychiatry Education Forum Academy! 13 years ago, I set out with a vision to help busy medical professionals by providing valuable psychiatric resources and insights. Initially, my goal was to help myself stay updated in the fast-evolving field of psychiatry. Today, I am filled with immense gratitude for the incredible growth and support our community has shown. It’s amazing to see how this platform has evolved to provide the same contributions to other busy medical professionals. What makes our forum truly unique is the collaborative educational support provided by both a psychiatrist (myself) and a family medicine physician (Dr. Kaur). This multidisciplinary approach ensures a comprehensive perspective on mental health, benefiting a wide range of medical professionals. To all our new and long-standing followers, thank you for being part of this journey. Whether you're looking to expand your knowledge, stay updated with the latest in psychiatry, or find practical tips for your practice, I’m proud that this forum can be a valuable resource for you. Join our growing community at Psychiatry Education Forum and let’s continue to navigate the fascinating world of psychiatry together. Join Academy Membership here : https://lnkd.in/gNCjBhK Blog Posts: https://lnkd.in/gyvK6_nx YouTube Channel: https://lnkd.in/ggv88XNS Instagram: https://lnkd.in/dUtNGkn Here’s to many more years of learning and growth!

?? Antidepressants & Hyponatremia Risk ?? ?? Key Findings from a Recent Meta-Analysis (European Psychiatry, 2024): ? Highest Risk: SNRIs (7.44%) > SSRIs (5.59%) > TCAs (2.66%) ? Lowest Risk: Mirtazapine (1.02%) & Trazodone (0.89%) ?? Clinical Takeaway: - When hyponatremia risk is a concern, mirtazapine may be the preferred antidepressant option. ?? Read our full blog post here: https://lnkd.in/gm7AZeeE ?? What are your preferred antidepressants in patients with hyponatremia risk? Let’s discuss in the comments! #Psychiatry #Antidepressants #Hyponatremia #ClinicalPractice #Psychopharmacology #MentalHealth #MedicalEducation

?? Stay Updated: Our Latest Psychiatry Blog Posts! We’ve been busy bringing you the latest updates in psychiatry! ?? Check out our recently posted blog articles designed to keep you informed with clinically relevant insights. ?? ?? Understanding Antidepressants’ Side Effects on Sleep: Sedation & Insomnia ?? https://lnkd.in/gT_7Myux ?? Maintenance Treatment in Bipolar Depression: What Recent Data Reveals ?? https://lnkd.in/guDHgSFt ?? Can Metformin Prevent Antipsychotic-Induced Weight Gain? ?? https://lnkd.in/gpfBmK2d ?? Brexpiprazole + Sertraline: Could this be the next FDA-approved treatment for PTSD? ?? https://lnkd.in/gzay26ye ?? FDA Eliminates Clozapine REMS Program: What This Means for Patients and Prescribers ?? https://lnkd.in/gdqkEY5v ?? Spravato: First Monotherapy FDA Approved for Treatment-Resistant MDD ?? https://lnkd.in/gDhezgrZ ?? Stay updated on the latest research & discussions—don't miss out! Which topic interests you the most? Drop a comment below! ????

Understanding Urine Drug Testing for Benzodiazepines - False positive results in urine drug tests for benzodiazepines can have serious consequences, impacting employment opportunities, legal matters, and personal well-being. - Understanding the factors that contribute to false positives and taking necessary precautions can help individuals navigate drug testing with greater confidence. Read our blog post here: https://lnkd.in/gfzEqrqk

?? Watch our Latest YouTube video: Brexpiprazole + Sertraline for PTSD: Exploring the Mechanism of Action PTSD remains a complex and challenging condition to treat, often requiring a combination of psychotherapy and pharmacological interventions. While sertraline has long been an FDA-approved treatment for PTSD, recent research suggests that adding brexpiprazole could enhance therapeutic outcomes. In this video, we explore the likely mechanism of action behind this combination, discussing how Brexpiprazole may complement Sertraline for PTSD symptoms. https://lnkd.in/gn3vaNqa

?? Could Brexpiprazole + Sertraline Be the Next FDA-Approved PTSD Treatment? ?? Exciting new research in PTSD treatment! The combination of Brexpiprazole + Sertraline is showing promising results in recent clinical trials. ?? Two key studies—published in JAMA Psychiatry (Dec 2024) and Journal of Clinical Psychiatry (Feb 2025)—evaluated this combination’s efficacy using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). ?? Primary Finding: By Week 10, patients on Brexpiprazole + Sertraline showed significant improvements in CAPS-5 scores, suggesting a potential breakthrough in PTSD management. ?? Read the blog post here: https://lnkd.in/gzay26ye

?? Upcoming Live Zoom Session: Register now – for Academy Members Only Brexpiprazole + Sertraline: Could this be the next FDA-approved treatment for PTSD? Join Dr. Harvinder Singh for an exclusive Academy Members-Only session exploring the latest research on Sertraline + Brexpiprazole as a potential FDA-approved treatment for PTSD. With recent studies under review, this session will provide key insights into clinical applications and practical dosing strategies. ?? Date & Time: Saturday, March 8 | 11:00 AM PST What You'll Learn: ?? Mechanism of action: How does this combination work for PTSD? ?? A breakdown of two recent studies (JAMA Psychiatry, Dec 2024 & Journal of Clinical Psychiatry, Feb 2025). ?? Weekly dosing strategies for Sertraline + Brexpiprazole. ?? Speed of response: How quickly were improvements seen? ?? Common side effects ?? Does Brexpiprazole + Sertraline differ from Brexpiprazole & Sertraline monotherapy in terms of response and adverse events? ?? Which PTSD symptoms did not show a positive response to this combination? ?? How this potential approval compares to past FDA indications and treatment guidelines. ?? This live session is exclusively for Academy Members. Only active Academy members will have their registration approved after signing up. Register now to secure your spot! Register here: https://lnkd.in/gzay26ye

?? Bipolar Depression: What Works for Long-Term Maintenance? ?? New data reveals which treatments can reduce the risk of depression-related hospitalization – and the findings might surprise you! ? Key Takeaways: ? Lithium is the ONLY monotherapy associated with a lower risk of hospitalization (HR 0.75, 95% CI: 0.67-0.85). ? No antidepressant monotherapy showed a protective effect. Read our recent blog post for more details: https://lnkd.in/guDHgSFt

Managing Clozapine's Adverse Events: Understanding the Basics & Beyond. - It is important for medical professionals to be aware of the presentation of?symptoms,?diagnostic findings,?and?management?of each adverse events. - This educational activity?will educate?practitioners about these adverse events so that they?feel confident?in weighing risks and benefits and consider prescribing clozapine to this treatment-resistant schizophrenia population. Learn more: https://lnkd.in/grCgWxPT

?? Big News: FDA Ends Clozapine REMS Program! ?? The FDA has officially eliminated the Clozapine REMS program, removing the requirement for frequent ANC monitoring before dispensing. This major update aims to improve patient access while maintaining essential safety measures. ?? We have summarized this topic in following sections: ? Why Was REMS Required for Clozapine? ? What This Change Means for Patients & Providers ? The Role of Advocacy & Clinical Perspectives ? Next Steps for Clinicians & Patients ?? Read here: https://lnkd.in/gdqkEY5v